Navigation Links
Project to capture and interrogate single cancer cells wins innovator award
Date:1/11/2013

HOUSTON From a single cell gone bad, cancer evolves into an increasingly complex tumor built of a variety of normal cells and diverse malignant cells, some of which escape to create dangerous colonies in other organs, further jumbling the treatment picture.

Nicholas Navin, Ph.D., an assistant professor in The University of Texas MD Anderson Cancer Center Department of Genetics, believes the key to sorting out this cellular chaos is by identifying important mutations in single tumor cells at various stages of the cancer's development.

Successfully analyzing differences in active mutations among cells would help researchers understand, map and eventually block the lethal path to metastasis spread of the primary cancer to other organs.

"The genetic diversity of tumor cells inhibits our understanding of metastasis. Single-cell sequencing will allow us to detail the genetic heterogeneity and trace the cell's lineage as mutations allow the cell to escape the primary tumor site, form a circulating cell and then seeds metastasis," Navin said. "Using genetic markers, we can reconstruct this evolutionary process."

The Damon Runyon Cancer Research Foundation wants Navin to test his idea, naming him the Nadia's Gift Foundation Innovator, one of its 2013 Damon Runyon-Rachleff Innovation Awards, providing $150,000 a year for three years.

Potential to predict metastasis, treatment response

Navin is one of seven early career scientists chosen for innovation awards because their projects have the potential to significantly improve prevention, diagnosis and treatment of cancer. The foundation announcement notes the innovation awards are for "cancer research by exceptionally creative thinkers with "high-risk/high-reward" ideas who lack sufficient preliminary data to obtain traditional funding."

The foundation noted that Navin's method "will have myriad clinical applications, which have prognostic value in predicting invasion, metastasis, survival and response to chemotherapy."

Navin is grateful to the foundation for support of the project, which he agrees is high-risk, high-reward because it aims to break new ground in the genomic analysis of cancer.

First, he must develop tools to reliably isolate individual cancer cells and identify mutations in all of the genes that encode proteins. Then he will apply single-cell gene sequencing to triple-negative breast cancer, the most lethal form of the disease.

Develop tools, apply them to triple-negative breast cancer

"Most of the tools we have now operate on bulk tumor tissue samples, which include normal supportive cells, or stroma, and immune system cells as well as cancer cells, which have different genetic mutations," Navin said. "So when we analyze tissue in bulk, we find the average genetic signal of the tumor. What you miss are the rare cells that may be most malignant."

Identifying these cells is particularly important for those with triple-negative breast cancer, which does not have the three protein targets that make other breast cancers much more treatable.

"Triple-negative breast cancer is the most aggressive type, with lowest survival rates, the most intratumor genetic heterogeneity, and it metastasizes the most," Navin said. "So there's really a dire need to help these patients by developing new therapies to inhibit metastasis."

To sequence the full coding regions of each single cell, Navin's lab will isolate single cells that have naturally doubled their chromosome content. The cell will be dissolved and the DNA will be expanded from picogram (trillionth of a gram) to nanogram (billionth) quantities using whole-genome amplification. This will provide sufficient material to generate libraries for 'next-generation' sequencing on the Illumina platform.

From this data, the full set of coding mutations can be detected in each cancer cell and compared to trace the lineage of their evolution during metastasis.

The project also will examine fundamental issues in cancer metastasis. "In cancer biology there's a big question about whether cells metastasize early in the growth of the primary tumor or if that occurs after the tumor has grown to a large size," Navin said. "Another model proposes that tumor cells can travel back and forth between primary and metastatic tumor sites. We're interested in looking at and understanding those models in triple- negative breast cancer."


'/>"/>

Contact: Scott Mervilloe
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. How the brains daily clock controls mood: A new project
2. Image share project gives patients and physicians anytime, anywhere access to medical images
3. Optogenetics project takes top NIDA Addiction Science Award
4. Leah Hoskins, F.I.L.M. Project Founder, Headed to Jail?
5. The W3 Project Receives Support from Doulton for Emergency Relief Efforts
6. Gene sequencing project identifies potential drug targets in common childhood brain tumor
7. Stanford Woods Institute for the Environment announces 2012 Environmental Venture Project awards
8. MyTownInsurance.com Reveals How Project CAP and Insurance Agoragate will Take Away Market Share from the Captive Insurance Carriers and give it back to the Independents
9. JHU Bioethics Institute receives PCORI pilot project award
10. UCLA-led project aimed at African American couples affected by HIV gets $2.5 million boost
11. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: